108 related articles for article (PubMed ID: 16685387)
1. GEP associates with wild-type p53 in hepatocellular carcinoma.
Cheung ST; Wong SY; Lee YT; Fan ST
Oncol Rep; 2006 Jun; 15(6):1507-11. PubMed ID: 16685387
[TBL] [Abstract][Full Text] [Related]
2. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma.
Cheung ST; Wong SY; Leung KL; Chen X; So S; Ng IO; Fan ST
Clin Cancer Res; 2004 Nov; 10(22):7629-36. PubMed ID: 15569995
[TBL] [Abstract][Full Text] [Related]
3. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma.
Moriyama Y; Nishiguchi S; Tamori A; Koh N; Yano Y; Kubo S; Hirohashi K; Otani S
Clin Cancer Res; 2001 May; 7(5):1293-8. PubMed ID: 11350897
[TBL] [Abstract][Full Text] [Related]
4. High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma.
Anzola M; Saiz A; Cuevas N; Lopez-Martinez M; Martinez de Pancorbo MA; Burgos JJ
J Viral Hepat; 2004 Nov; 11(6):502-10. PubMed ID: 15500550
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation.
Caruso ML; Valentini AM
Anticancer Res; 1999; 19(5B):3853-6. PubMed ID: 10628323
[TBL] [Abstract][Full Text] [Related]
6. RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: its application as a therapeutic agent.
Park MY; Park YS; Nam JH
Int J Oncol; 2011 Oct; 39(4):853-61. PubMed ID: 21701774
[TBL] [Abstract][Full Text] [Related]
7. Binding of wild-type p53 by topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma.
Yuwen H; Hsia CC; Nakashima Y; Evangelista A; Tabor E
Biochem Biophys Res Commun; 1997 May; 234(1):194-7. PubMed ID: 9168988
[TBL] [Abstract][Full Text] [Related]
8. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma.
Hsia CC; Nakashima Y; Thorgeirsson SS; Harris CC; Minemura M; Momosaki S; Wang NJ; Tabor E
Oncol Rep; 2000; 7(2):353-6. PubMed ID: 10671685
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1.
Chen Ban K; Singh H; Krishnan R; Fong Seow H
J Surg Oncol; 2004 Jun; 86(3):157-63. PubMed ID: 15170655
[TBL] [Abstract][Full Text] [Related]
11. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.
Cheung PF; Yip CW; Wong NC; Fong DY; Ng LW; Wan AM; Wong CK; Cheung TT; Ng IO; Poon RT; Fan ST; Cheung ST
Cancer Immunol Res; 2014 Dec; 2(12):1209-19. PubMed ID: 25315249
[TBL] [Abstract][Full Text] [Related]
12. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
Kubicka S; Trautwein C; Niehof M; Manns M
Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
[TBL] [Abstract][Full Text] [Related]
13. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma.
Ho JC; Ip YC; Cheung ST; Lee YT; Chan KF; Wong SY; Fan ST
Hepatology; 2008 May; 47(5):1524-32. PubMed ID: 18393387
[TBL] [Abstract][Full Text] [Related]
14. Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells.
Li YX; Lin ZB; Tan HR
Acta Pharmacol Sin; 2004 Jan; 25(1):76-82. PubMed ID: 14704126
[TBL] [Abstract][Full Text] [Related]
15. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma.
Volkmann M; Schiff JH; Hajjar Y; Otto G; Stilgenbauer F; Fiehn W; Galle PR; Hofmann WJ
J Mol Med (Berl); 2001 Oct; 79(10):594-600. PubMed ID: 11692157
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients.
Tseng PL; Tai MH; Huang CC; Wang CC; Lin JW; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
J Surg Oncol; 2008 Oct; 98(5):349-57. PubMed ID: 18646041
[TBL] [Abstract][Full Text] [Related]
17. RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.
Xue WJ; Li C; Zhou XJ; Guan HG; Qin L; Li P; Wang ZW; Qian HX
J Gastroenterol Hepatol; 2008 Sep; 23(9):1448-58. PubMed ID: 17683489
[TBL] [Abstract][Full Text] [Related]
18. TIP30 mutant derived from hepatocellular carcinoma specimens promotes growth of HepG2 cells through up-regulation of N-cadherin.
Jiang C; Pecha J; Hoshino I; Ankrapp D; Xiao H
Cancer Res; 2007 Apr; 67(8):3574-82. PubMed ID: 17440068
[TBL] [Abstract][Full Text] [Related]
19. Expression and role of SIRT1 in hepatocellular carcinoma.
Choi HN; Bae JS; Jamiyandorj U; Noh SJ; Park HS; Jang KY; Chung MJ; Kang MJ; Lee DG; Moon WS
Oncol Rep; 2011 Aug; 26(2):503-10. PubMed ID: 21567102
[TBL] [Abstract][Full Text] [Related]
20. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
